SBP 002

Drug Profile

SBP 002

Alternative Names: Coramsine; SBP 002 cream - Solbec; SBP002; Solasonine/solamargine

Latest Information Update: 12 Nov 2010

Price : $50

At a glance

  • Originator Solbec Pharmaceuticals
  • Developer Freedom Eye
  • Class Antineoplastics; Immunotherapies; Skin disorder therapies; Solanaceous alkaloids
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Renal cancer

Highest Development Phases

  • No development reported Psoriasis; Renal cancer; Solid tumours

Most Recent Events

  • 05 Dec 2008 Solbec is now called Freedom Eye Limited
  • 19 May 2008 SBP 002 is available for licensing worldwide (http://www.solbec.com.au)
  • 04 Feb 2008 Use of SBP 002 for the single use treatment of a US patient with advanced RCC has been discontinued
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top